Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- 5 December 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (1), 27-38
- https://doi.org/10.1016/s1470-2045(15)00464-7
Abstract
No abstract availableFunding Information
- Onyx Pharmaceuticals
This publication has 22 references indexed in Scilit:
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesHaematologica, 2013
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsBlood, 2010
- Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-livedEuropean Journal of Haematology, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With BortezomibJournal of Clinical Oncology, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaThe New England Journal of Medicine, 2003
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983